Richardson directs the Global Medical Innovation (GMI) track in Rice's Master of Bioengineering (M.B.E.) program, and is an instructor and mentor for undergraduate project-based engineering design courses at Riceâ€™s Oshman Engineering Design Kitchen (OEDK). His particular interests include developing medical technologies for global settings. In 2015, he helped launch TMC Biodesign, a fellowship program that offers design thinking, product development and venture formation curriculum and mentorship for medical device and digital health startups. Currently, Richardson serves as the associate director of the TMC Biodesign program, which is part of the TMC Innovation Institute.
In addition to educating and guiding students through the process of product development and implementation, Richardson builds programs in education, training and professional development for Riceâ€™s professional masterâ€™s program in bioengineering. These programs are leveraged through growing ties with industry and government, institutes of the Texas Medical Center, and Rice University research centers and institutes, such as the Rice Alliance for Technology and Entrepreneurship (Rice Alliance), OEDK, and Rice 360Â° Institute for Global Health. Richardson's exceptional efforts in instructional design and course management have been recognized through the Department of Bioengineering's Teaching Award (2014).
Through his doctoral studies in biomedical engineering with Paul Laizzo, professor of surgery, and integrative biology and physiology at the University of Minnesotaâ€™s Medical School, and as a scientist and R&D engineer at Medtronic, Richardson has 12 years of experience in translational research focused on cardiovascular medical device design and cardiovascular combination therapies. Results of his graduate and industry work have led to several patents, publications, and book chapters.
Prior to joining Rice in 2013, he was a senior and principal R&D engineer at Medtronic and member of the companyâ€™s Leadership Development Program. There he worked on CoreValve, one of the worldâ€™s first transcatheter aortic valves, which has been implanted in over 100,000 patients. He also led a project team of several engineers, scientists and technicians to develop a second-generation transcatheter tissue heart valve, the CoreValve Evolut R, which now has FDA approval.